Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,305Revenue $M107Net Margin (%)-35.2Altman Z-Score7.9
Enterprise Value $M2,214EPS $-0.3Operating Margin %-30.4Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-35.2Higher ROA y-yY
Price/Book46.310-y EBITDA Growth Rate %7.3Quick Ratio4.6Cash flow > EarningsY
Price/Sales21.15-y EBITDA Growth Rate %0.7Current Ratio4.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-22.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-83.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M128ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOFirst Eagle Investment 2015-06-30 Add0.02%$14.28 - $22.58
($17.52)
$ 18.043%Add 8.55%4,162,000
HALOJoel Greenblatt 2015-06-30 Buy 0.01%$14.28 - $22.58
($17.52)
$ 18.043%New holding36,701
HALOKen Fisher 2015-06-30 Reduce$14.28 - $22.58
($17.52)
$ 18.043%Reduce 2.86%740,955
HALOFirst Eagle Investment 2015-03-31 Reduce$9.82 - $16.2
($14.42)
$ 18.0425%Reduce 3.92%3,834,050
HALOFirst Eagle Investment 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 18.0489%Add 30.25%3,640,480
HALOFirst Eagle Investment 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 18.04113%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 18.04113%New holding791,760
HALOFirst Eagle Investment 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 18.0440%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 18.04120%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 18.04173%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.244.64view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.244.64view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-14.1view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.3317.68view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.9102.7view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.92102.24view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9681.12view
Engler RobertDirector 2014-08-14Sell35,000$9.9681.12view
Engler RobertDirector 2014-05-15Sell126,700$7.56138.62view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1397.59view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
buffet May 31 2015 
buffet May 31 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
comment on HALO May 12 2013 
comment on HALO May 12 2013 
comment on HALO May 12 2013 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Halozyme Appoints Michael J. Labarre As Chief Scientific Officer Aug 24 2015
Halozyme Appoints Michael J. Labarre As Chief Scientific Officer Aug 24 2015
Halozyme Enzyme Could Boost Power Of Cancer Drugs Aug 24 2015
HALOZYME THERAPEUTICS INC Financials Aug 20 2015
10-Q for Halozyme Therapeutics, Inc. Aug 12 2015
Halozyme Stock Reverses Despite AbbVie-Fueled Earnings Aug 11 2015
Halozyme Stock Surges As AbbVie Deal Pays Off Aug 11 2015
Halozyme (HALO) Stock Spikes Following Earnings Release Aug 11 2015
Edited Transcript of HALO earnings conference call or presentation 10-Aug-15 8:30pm GMT Aug 10 2015
Halozyme Therapeutics beats 2Q profit forecasts Aug 10 2015
Halozyme Therapeutics beats 2Q profit forecasts Aug 10 2015
Halozyme Reports Second Quarter 2015 Financial Results Aug 10 2015
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
Halozyme Reports Second Quarter 2015 Financial Results Aug 10 2015
Q2 2015 Halozyme Therapeutics Inc Earnings Release - After Market Close Aug 10 2015
UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially... Aug 06 2015
UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially... Aug 06 2015
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Aug 06 2015
Halozyme Appoints Jeffrey W. Henderson To Board Aug 05 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK